{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:59:35Z","timestamp":1785207575206,"version":"3.55.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016305","name":"First Affiliated Hospital of Zhengzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pnpbp.2026.111727","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:29:20Z","timestamp":1778167760000},"page":"111727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative network pharmacology analysis of ketamine and xanomeline in major depressive disorder: Shared and distinct molecular mechanisms"],"prefix":"10.1016","volume":"147","author":[{"given":"Xin","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0005","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41380-024-02729-9","article-title":"Allosteric inhibition of NMDA receptors by low dose ketamine","volume":"30","author":"Abbott","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0010","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","author":"Acevedo-Diaz","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0015","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/acschemneuro.7b00001","article-title":"Classics in chemical neuroscience: xanomeline","volume":"8","author":"Bender","year":"2017","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","article-title":"Protein data bank (PDB): the single global macromolecular structure archive","volume":"1607","author":"Burley","year":"2017","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2025.104502","article-title":"Advances in the study of NMDA receptors in depression pathogenesis and the antidepressant efficacy of their antagonists","volume":"108","author":"Chen","year":"2025","journal-title":"Asian J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0030","article-title":"Novel drug treatment for schizophrenia","author":"Coyle","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-024-01738-y","article-title":"Major depressive disorder: hypothesis, mechanism, prevention and treatment","volume":"9","author":"Cui","year":"2024","journal-title":"Signal Trans. Target. Ther."},{"issue":"W1","key":"10.1016\/j.pnpbp.2026.111727_bb0040","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0045","article-title":"Psychedelics and ketamine\/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes","volume":"15","author":"d'Andrea","year":"2025","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111727_bb0050","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2174\/1568026620666200131100316","article-title":"An update on glutamatergic system in suicidal depression and on the role of esketamine","volume":"20","author":"De Berardis","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0055","first-page":"344","article-title":"Ras and Rab interactor 1 controls neuronal plasticity by coordinating dendritic filopodial motility and AMPA receptor turnover","volume":"39","author":"De Roo","year":"2008","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107510","article-title":"IUPHAR review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia","volume":"210","author":"Dean","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41398-022-01943-9","article-title":"IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine","volume":"12","author":"Deyama","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuroscience.2016.03.056","article-title":"The role of Insulin-Like Growth Factor 1 (IGF-1) in brain development, maturation and neuroplasticity","volume":"325","author":"Dyer","year":"2016","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111727_bb0075","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.drudis.2019.08.009","article-title":"Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders","volume":"24","author":"Erskine","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.119817","article-title":"Change in global burden of depressive and anxiety disorders due to pandemic: insight from GBD 2021","volume":"390","author":"Fan","year":"2025","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0085","first-page":"22","article-title":"SSRI antidepressant medications: adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim. Care Compan. CNS Disord."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111727_bb0090","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00406-024-01875-z","article-title":"Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression","volume":"275","author":"Freudenberg","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0095","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111727_bb0100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archpsyc.63.10.1121","article-title":"Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial","volume":"63","author":"Furey","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"W1","key":"10.1016\/j.pnpbp.2026.111727_bb0105","doi-asserted-by":"crossref","first-page":"W726","DOI":"10.1093\/nar\/gkac297","article-title":"SuperPred 3.0: drug classification and target prediction-a machine learning approach","volume":"50","author":"Gallo","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111727_bb0110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1192\/bjp.2024.275","article-title":"Examining the needs, outcomes and current treatment pathways of 2461 people with treatment-resistant depression: mixed-methods study","volume":"228","author":"Gill","year":"2026","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156663","article-title":"Luteolin inhibits inflammation and M1 macrophage polarization in the treatment of Pseudomonas aeruginosa-induced acute pneumonia through suppressing EGFR\/PI3K\/AKT\/NF-\u03baB and EGFR\/ERK\/AP-1 signaling pathways","volume":"141","author":"Gu","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"6747","key":"10.1016\/j.pnpbp.2026.111727_bb0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1126\/science.adx4559","article-title":"Extending ketamine's antidepressant effects","volume":"388","author":"Hashimoto","year":"2025","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111727_bb0130","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00406-024-01770-7","article-title":"Are \"mystical experiences\" essential for antidepressant actions of ketamine and the classic psychedelics?","volume":"275","author":"Hashimoto","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jatmed.2024.07.001","article-title":"Ketamine and its two enantiomers in anesthesiology and psychiatry: a historical review and future directions","volume":"3","author":"Hashimoto","year":"2024","journal-title":"J. Anes. Transl. Med."},{"issue":"28","key":"10.1016\/j.pnpbp.2026.111727_bb0140","doi-asserted-by":"crossref","first-page":"eadv5986","DOI":"10.1126\/sciadv.adv5986","article-title":"Microglial BDNF modulates arketamine's antidepressant-like effects through cortico-accumbal pathways","volume":"11","author":"He","year":"2025","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111727_bb0145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nature Chem. Biol."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.120201","article-title":"Global burden of anxiety, depression, and self-harm (1990-2021) and the impact of the COVID-19 pandemic","volume":"392","author":"Jang","year":"2026","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111727_bb0155","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2174\/1570159X13666150612230045","article-title":"The role of muscarinic receptors in the pathophysiology of mood disorders: a potential novel treatment?","volume":"13","author":"Jeon","year":"2015","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111727_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad014","article-title":"Comprehensive assessment of nine target prediction web services: which should we choose for target fishing?","volume":"24","author":"Ji","year":"2023","journal-title":"Briefings Bioinform."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111727_bb0165","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00406-023-01732-5","article-title":"The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database","volume":"275","author":"Jiang","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2025.05.029","article-title":"Drug-related suicidal ideation in the K-12 population: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS) database","volume":"188","author":"Ju","year":"2025","journal-title":"J. Psychiatr. Res."},{"issue":"10422","key":"10.1016\/j.pnpbp.2026.111727_bb0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111727_bb0180","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0185","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/appi.ajp.20241186","article-title":"Long-term safety and efficacy of xanomeline and trospium chloride in schizophrenia: a 52-week open-label extension trial","volume":"183","author":"Kaul","year":"2026","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111727_bib396","doi-asserted-by":"crossref","first-page":"104448","DOI":"10.1016\/j.ajp.2025.104448","article-title":"Neuroscience in pictures: 4. depression","volume":"107","author":"Keshavan","year":"2025","journal-title":"Asian J. Psychiatry"},{"issue":"D1","key":"10.1016\/j.pnpbp.2026.111727_bb0190","doi-asserted-by":"crossref","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","article-title":"PubChem in 2021: new data content and improved web interfaces","volume":"49","author":"Kim","year":"2021","journal-title":"Nucl. Acids Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0195","article-title":"A global population-based study on the association between ketamine and esketamine with suicidality using WHO VigiBase","volume":"86","author":"Kwan","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110595","article-title":"Levomilnacipran ameliorates lipopolysaccharide-induced depression-like behaviors and suppressed the TLR4\/Ras signaling pathway","volume":"122","author":"Li","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-0716-3441-7_6","article-title":"Protein-ligand blind docking using CB-Dock2","volume":"2714","author":"Liu","year":"2024","journal-title":"Methods Mol. Biology (Clifton, N.J.)"},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111727_bb0210","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/s44318-025-00390-8","article-title":"Different Ras isoforms regulate synaptic plasticity in opposite directions","volume":"44","author":"L\u00f3pez-Merino","year":"2025","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s12991-023-00478-7","article-title":"Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel","volume":"22","author":"Maina","year":"2023","journal-title":"Ann. Gen. Psychiatry"},{"issue":"10161","key":"10.1016\/j.pnpbp.2026.111727_bb0220","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0225","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111727_bb0230","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/biomedicines11102636","article-title":"The potential of scopolamine as an antidepressant in major depressive disorder: a systematic review of randomized controlled trials","volume":"11","author":"Mo\u0107ko","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111727_bb0235","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41386-020-00916-0","article-title":"The M1\/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain","volume":"46","author":"Montani","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0240","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-pharmtox-051921-023858","article-title":"Targeting the actions of muscarinic receptors on dopamine systems: new strategies for treating neuropsychiatric disorders","volume":"64","author":"Nunes","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0245","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1566524015666150330143008","article-title":"Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders","volume":"15","author":"Ohgi","year":"2015","journal-title":"Curr. Mol. Med."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0250","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yfrne.2012.06.002","article-title":"Neurodevelopmental effects of insulin-like growth factor signaling","volume":"33","author":"O'Kusky","year":"2012","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2026.e00839","article-title":"Targeting muscarinic receptors for treating schizophrenia","author":"Paul","year":"2026","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00228-025-03954-z","article-title":"A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals","volume":"82","author":"Pisanu","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0265","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0270","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-024-05003-3","article-title":"Antidepressant nonadherence and sexual dysfunction among young adult males: the cross-sectional YAMAN study","volume":"42","author":"Rabinowitz","year":"2024","journal-title":"World J. Urol."},{"issue":"14","key":"10.1016\/j.pnpbp.2026.111727_bb0275","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0280","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baw100","article-title":"The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins","volume":"2016","author":"Rouillard","year":"2016","journal-title":"Database (Oxford)"},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111727_bib397","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0285","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baq020","article-title":"GeneCards version 3: the human gene integrator","volume":"2010","author":"Safran","year":"2010","journal-title":"Database (Oxford)"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111727_bb0290","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrn1368","article-title":"Src kinases: a hub for NMDA receptor regulation","volume":"5","author":"Salter","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111727_bb0295","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111727_bb0300","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111727_bb0305","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neuron.2015.10.039","article-title":"M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia","volume":"88","author":"Shen","year":"2015","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","article-title":"Targeting RAS\u2013RAF\u2013MEK\u2013ERK signaling pathway in human cancer: current status in clinical trials","volume":"10","author":"Song","year":"2023","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0315","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1073858410365562","article-title":"Ras and Rap signaling in synaptic plasticity and mental disorders","volume":"17","author":"Stornetta","year":"2011","journal-title":"Neuroscientist"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0320","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40265-024-02126-0","article-title":"Xanomeline\/trospium chloride: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"issue":"D1","key":"10.1016\/j.pnpbp.2026.111727_bb0325","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucl. Acids Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111727_bb0330","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"D1","key":"10.1016\/j.pnpbp.2026.111727_bb0335","doi-asserted-by":"crossref","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: the universal protein knowledgebase in 2021","volume":"49","author":"UniProt Consortium","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111727_bb0340","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40263-022-00964-8","article-title":"Clinical effectiveness of muscarinic receptor-targeted interventions in neuropsychiatric disorders: a systematic review","volume":"36","author":"Vaidya","year":"2022","journal-title":"CNS Drugs"},{"issue":"W1","key":"10.1016\/j.pnpbp.2026.111727_bb0345","doi-asserted-by":"crossref","first-page":"W356","DOI":"10.1093\/nar\/gkx374","article-title":"PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database","volume":"45","author":"Wang","year":"2017","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107236","article-title":"Dynamic regulation of phosphorylation of NMDA receptor GluN2B subunit tyrosine residues mediates ketamine rapid antidepressant effects","volume":"205","author":"Wang","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0355","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"D1","key":"10.1016\/j.pnpbp.2026.111727_bb0360","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.pnpbp.2026.111727_bb0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.apha.2020.03.003","article-title":"Involvement of muscarinic receptor mechanisms in antidepressant drug action","volume":"89","author":"Witkin","year":"2020","journal-title":"Adv. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0370","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111727_bb0375","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111727_bb0380","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.86022","article-title":"Ketamine\u2019s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors","volume":"12","author":"Zaytseva","year":"2023","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0385","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41398-020-0733-x","article-title":"Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111727_bb0390","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"issue":"D1","key":"10.1016\/j.pnpbp.2026.111727_bb0395","doi-asserted-by":"crossref","first-page":"D1465","DOI":"10.1093\/nar\/gkad751","article-title":"TTD: therapeutic target database describing target druggability information","volume":"52","author":"Zhou","year":"2024","journal-title":"Nucl. Acids Res."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626001247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626001247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:29:55Z","timestamp":1785205795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626001247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":81,"alternative-id":["S0278584626001247"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111727","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative network pharmacology analysis of ketamine and xanomeline in major depressive disorder: Shared and distinct molecular mechanisms","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111727"}}